Founded in 2010, Crystal Pharmatech has been recognized as the leading technology-driven contract research organization (CRO) in solid-state research, crystallization process development, and preformulation studies. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in innovative drugs so that our customers can reap the benefits of fundamental discoveries in an ever-changing field.
Crystal Pharmatech was founded by Alex Chen, Yanfeng Zhang, and Robert Wenslow in Biobay, Suzhou Industrial Park (SIP), China.
Crystal Pharmatech had raised $1.48 Million to accelerate growth in Angel Round funding.
Crystal Pharmatech tripled its headquarters in Biobay, Suzhou Industrial Park (SIP), China with more floors and labs.
New Labs had been established in NJ, US.
Crystal Pharmatech has raised a total of $10 million in Series A Round funding.
Crystal Pharmatech's full subsidiary Crystal Pharmaceutical was established.
Crystal Pharmatech's Canadian subsidiary Candoo Pharmatech was established, which is a technology-driven biopharmaceutical company specializing in formulation and drug delivery solutions for small and large molecules.
Crystal Pharmatech's full subsidiary Crystal Formulation Services (CFS) was established, providing oral formulation development and manufacturing services for innovative drug products around the world.